PMID- 21650061
OWN - NLM
STAT- MEDLINE
DCOM- 20111024
LR  - 20110608
IS  - 2096-7993 (Print)
IS  - 2096-7993 (Linking)
VI  - 25
IP  - 6
DP  - 2011 Mar
TI  - [The expression and correlation of HMGB1 and VEGF protein in laryngeal squamous 
      cell carcinoma].
PG  - 265-9
AB  - OBJECTIVE: To investigate the expression and biological significance of HMGB1 and 
      VEGF protein in tissue specimens of laryngeal squamous cell carcinoma (LSCC), and 
      further study the correlation between HMGB1 and VEGF protein. METHOD: The 
      expression of HMGB1 and VEGF protein was evaluated by immunohistochemical 
      staining in 69 cases of LSCC specimens and 15 cases of adjacent epithelial tissue 
      samples, and futher correlated with clinicopathologic parameters. RESULT: The 
      positive rates of HMGB1 and VEGF in LSCC tissues were significantly higher than 
      those in adjacent non-cancerous mucosa (P < 0.01), and the expression of these 
      two marks was closely correlated with clinical stage (P < 0.05) and metastasis (P 
      < 0.05) in LSCC. While the expression of HMGB1 and VEGF had no significant 
      correlations with age, sex, histological differentiation and tumor site (P > 0. 
      05). There was a positive correlation between the expression of HMGB1 and VEGF (P 
      < 0.05). The Kaplan-Meier survival analysis showed that patients with strong 
      expression of HMGB1 or VEGF had poorer overall survival compared with that in 
      patients with relative low HMGB1 or VEGF expression (P < 0.05). Multivariate COX 
      regression analysis revealed that both lymph node metastasis and HMGB1 expression 
      were independent prognostic factors for patients with LSCC. CONCLUSION: This 
      study demonstrated that HMGB1 and VEGF protein overexpression were closely 
      associated with clinical stage, metastasis and poorer prognosis in patients with 
      LSCC. Increased expression of these two proteins in LSCC suggested that HMGB1 and 
      VEGF might play a critical role in the initiation and progression of LSCC.
FAU - Liu, Yong
AU  - Liu Y
AD  - Department of Otorhinolaryngology, Xiangya Hospital, Central South University, 
      Changsha, 410008, China.
FAU - Qiu, Yuanzhenk
AU  - Qiu Y
FAU - Zhang, Xin
AU  - Zhang X
FAU - Tian, Yongquan
AU  - Tian Y
FAU - Huang, Donghai
AU  - Huang D
FAU - Zhou, Xiaojuan
AU  - Zhou X
FAU - Tan, Pingqing
AU  - Tan P
FAU - Yu, Changyun
AU  - Yu C
FAU - Qi, Lin
AU  - Qi L
FAU - Xiao, Jianyun
AU  - Xiao J
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
JT  - Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical 
      otorhinolaryngology, head, and neck surgery
JID - 101303164
RN  - 0 (HMGB1 Protein)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/*metabolism/pathology
MH  - Female
MH  - HMGB1 Protein/*metabolism
MH  - Humans
MH  - Laryngeal Neoplasms/*metabolism/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Vascular Endothelial Growth Factor A/*metabolism
EDAT- 2011/06/10 06:00
MHDA- 2011/10/25 06:00
CRDT- 2011/06/10 06:00
PHST- 2011/06/10 06:00 [entrez]
PHST- 2011/06/10 06:00 [pubmed]
PHST- 2011/10/25 06:00 [medline]
PST - ppublish
SO  - Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Mar;25(6):265-9.